HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH POST-STROKE SPASTICITY BEFORE AND AFTER SPASTICITY MANAGEMENT INCLUDING ONABOTULINUMTOXINA

Alberto ESQUENAZI, MD1, Lisa BLOUDEK, PharmD, MS2, Kristen MIGLIACCIO-WALLE, BS3, David OLIVERI, BS3, Amy TUNG, PharmD, MS4, Patrick GILLARD, PharmD, MS4, Monica VERDUZCO-GUTIERREZ, MD5

From the 1MossRehab Gait and Motion Analysis Laboratory, Elkins Park, PA, 2Curta, Inc., Seattle, WA, 3Genesis Research, Hoboken, NJ, 4Allergan, an AbbVie Company, Chicago, IL, and 5Long School of Medicine at UT Health, San Antonio, TX, USA

Background: Real-world data regarding the impact of onabotulinumtoxinA on healthcare resource utilization and costs for post-stroke spasticity are scarce. Objective: To compare differences in 12-month healthcare resource utilization and costs before and after post-stroke spasticity management including onabotulinumtoxinA.

Methods: This retrospective claims analysis of IBM MarketScan Commercial and Medicare Supplemental databases included adults with ≥ 1 onabotulinumtoxinA claim for post-stroke spasticity (1 January 2010 to 30 June 2018) and continuous enrolment for ≥ 12 months pre- and post-index (first onabotulinumtoxinA claim date). All-cause and spasticity-related healthcare resource utilization and costs were compared 12 months pre- and post-index (McNemar’s χ2 test or paired t-test). A subgroup analysis assessed effect of stroke-to-index-date interval on costs.

Results: Among 735 patients, mean (standard deviation) stroke-date-to-index-date interval was 284.5 (198.8) days. Decreases were observed post-index for mean all-cause outpatient (62.9 vs 60.5; p ≤ 0.05) and emergency department visits (1.1 vs 0.8; p ≤ 0.0001), and hospital admissions (1.5 vs 0.4; p ≤ 0.0001). Increase in prescription fills (43.0 vs 53.7) was seen post-index. Post-index decreases in all-cause (–66%) and spasticity-related (–51%) costs were driven by reduced inpatient care costs. Findings were consistent regardless of stroke-date-to-index-date interval.

Conclusion: Significant reductions in healthcare resource utilization and costs were observed after 1 year of post-stroke spasticity management including onabotulinumtoxinA. Long-term studies are needed to establish causality.

Key words: botulinum toxins, type A; cost analysis; health resources; muscle spasticity; stroke.

Accepted Sep 26, 2023


DOI: 10.2340/jrm.v55.11626

P

Post-stroke spasticity (PSS) is a debilitating condition characterized by intermittent or sustained involuntary muscle activation resulting from a central sensorimotor network lesion in the brain or spinal cord (1, 2). Spasticity occurs in approximately 20–40% of patients in the first 6 months to 1 year following a stroke (3–8), and 2–13% of patients develop disabling spasticity (9). For a patient in the chronic phase of stroke recovery, the presence of spasticity represents a barrier to positive outcomes from subacute stroke rehabilitation and is associated with a negative impact on quality of life (2, 8). Following discharge from hospital after a stroke, patients with spasticity have longer stays in the inpatient rehabilitation clinic than patients without spasticity; in 1 prospective study, 53.2% of patients with spasticity had an inpatient stay longer than 5 weeks compared with 35.8% of patients without spasticity (3).

Overall, the economic burden of stroke care is high, particularly in patients with a greater level of functional
Impairment and during the first 1–3 months following a stroke (10–12). Healthcare costs are 2–4 times higher for stroke survivors with spasticity than for those without spasticity (13, 14). PSS is also associated with symptoms such as pain, contractures, immobilization in abnormal limb postures, and development of pressure sores (2, 4, 15). Furthermore, PSS increases caregiver burden, productivity loss, and indirect costs associated with caring for patients with spasticity (16).

Botulinum toxins type A (BoNT/A), including onabotulinumtoxinA, are indicated for the treatment of upper- and lower-limb spasticity based on randomized controlled clinical trials that demonstrated reductions in predetermined disability parameters, including pain, and reductions in caregiver burden (17–22). In the observational, real-world Adult Spasticity International Registry (ASPIRE) study, onabotulinumtoxinA treatment for PSS demonstrated high patient and clinician satisfaction with treatment efficacy (23). OnabotulinumtoxinA treatment also helped patients participate in therapy/exercise, reduced Disability Assessment Scale scores (dressing, hygiene, limb posture, pain), and reduced patient-reported spasticity-related pain (23). Studies have suggested that BoNT/A treatment is cost-effective and reduces disease burden, as evidenced by increased quality-adjusted life years, in patients with PSS (24, 25). However, there is a paucity of information regarding the impact of onabotulinumtoxinA treatment on healthcare resource utilization (HRU) and costs for patients with PSS.

The primary objective of this retrospective claims data analysis was to assess the impact of comprehensive spasticity management including onabotulinumtoxinA treatment on HRU and costs among patients diagnosed with PSS by comparing differences in 12-month HRU and costs before vs after initiation of onabotulinumtoxinA treatment.

**Methods**

The study design was a retrospective analysis of claims data from the IBM MarketScan Commercial and Medicare Supplemental databases (2009–2019). The IBM MarketScan Commercial database consists of health insurance claims for inpatient, outpatient, and outpatient pharmacy visits and enrolment data from employers and health plans across the USA, whereas the Medicare Supplemental database includes enrolment records and claims data for inpatient, outpatient, ancillary, and drug claims for retirees in the USA with Medicare supplemental insurance. These databases comprise integrated, patient-level health records that provide a comprehensive view of HRU and costs, with de-identified records of more than 270 million individual patients linked via unique identifiers to provide robust, longitudinal data, which are geographically representative of the US population (26).

Patients were identified using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and Tenth Revision, Clinical Modification (ICD-10-CM), and procedure codes (Table S1). The first onabotulinumtoxinA claim for PSS identified in the study period was assigned as the index date. HRU and costs were compared between the 12-month pre- and post-index periods.

Patient records were de-identified in agreement with US guidelines for patient confidentiality, including the 1996 Health Insurance Portability and Accountability Act, as certified by an independent third party. This study did not require institutional review board approval because only de-identified patient records were used and no individually identifiable data were collected, used, or transmitted.

**Patient selection**

Eligible patients were adults ≥ 18 years with ≥ 1 onabotulinumtoxinA claim for PSS between 1 January 2010, and 30 June 2018, and continuous enrolment for ≥ 12 months before and after the index date. Key exclusion criteria were spasticity unrelated to stroke; any use of onabotulinumtoxinA prior to index date; use of other toxins at any time during the study period; documented evidence of contracture within 12 months prior to index date; and acute stroke within 12 months following the index date.

**Study outcomes**

All-cause and spasticity-related HRU were assessed 12 months before and after index treatment with onabotulinumtoxinA and included outpatient visits, emergency department (ED) visits, hospitalizations, and prescriptions. All-cause and spasticity-related costs were evaluated 12 months before and after index treatment with onabotulinumtoxinA and included costs overall and by category (i.e. outpatient, ED, inpatient, and pharmacy). Spasticity-related costs were determined using inpatient stay records that included any of the ICD-10-CM codes noted in Table S1 as the primary diagnosis. Service codes for other outpatient claims (occupational therapy and physical therapy) are shown in Table S1. Because stroke itself can be a high-cost event and may overwhelm any meaningful differences in HRU and costs, a sensitivity analysis was conducted to evaluate all-cause and spasticity-related costs for subgroups stratified by time between index date and
the most recent stroke diagnosis (≤ 180 vs > 180 days and ≤ 365 vs > 365 days).

Statistical analysis

HRU was determined by counting claims that occurred within the 12-month pre- and post-index period for inpatient admissions, outpatient visits, ED visits, and prescriptions filled. For HRU, number of visits/admissions per patient, visits/admissions per patient with at least one visit/admission, number of prescriptions filled per patient, and numbers of prescriptions filled per patient with at least one prescription fill were summarized categorically by visit/admission as patients with ≥1 utilized, ≥2 utilized, and ≥3 utilized. Unadjusted costs were calculated for the 12 months pre- and post-index date including means (SD) and first and third quartiles across mutually exclusive categories. Mean costs per patient were reported for the following categories: outpatient visits, ED visits, inpatient admissions, and numbers of prescriptions filled, as well as a total cost calculated by summing all these categories. HRU and costs were then compared between the pre- and post-index periods within the onabotulinumtoxinA-treated cohort. The significance of observed differences in HRU and cost outcomes measured continuously were measured using the paired \( t \)-test (mean) and Wilcoxon signed rank test (median). Pre- and post-index period comparisons were analysed using McNemar’s \( \chi^2 \) test (categorical variables) and the paired \( t \)-test (continuous variables).

RESULTS

Cohort attrition and baseline characteristics

Of 352,064 patients identified with an initial spasticity diagnosis between 1 January 2010 and 30 June 2018, 2,696 patients also received onabotulinumtoxinA for PSS during this period, and a total of 735 patients met all eligibility requirements and were included in this analysis. Cohort attrition is shown in Table SIII. More than half (54%) of the patients were male, with a mean age at index date of 60.7 years, and 65% were enrolled in a commercial insurance plan (vs 35% in Medicare) (Table I). The most common comorbidities were cerebrovascular disease, hemiplegia, diabetes without chronic complication, and peripheral vascular disease (Table I).

Mean (SD) time from stroke to initial spasticity diagnosis was 27.1 (85.9) days, and mean (SD) time from stroke diagnosis to index date was 284.5 (198.8) days. A total of 542 patients had a confirmed diagnosis of stroke prior to the index date and were included in the sensitivity analysis; of these patients, the majority had been diagnosed with stroke more than 6 months (67%; \( n = 361 \)) but less than 1 year (77%; \( n = 420 \)) before the index date (Table I).

Healthcare resource utilization outcomes

Overall, utilization of all-cause outpatient services was similar in the pre- and post-index periods (mean (SD) 62.9 (42.9) and 60.5 (46.9) visits, respectively; \( p = 0.16 \) (Fig. 1). Significant reductions were observed in the use of outpatient primary care and other specialists (\( p \leq 0.05 \)) in the post-index period, whereas there were significant increases in outpatient visits to a neurologist and for physical medicine and occupational therapy (\( p \leq 0.05 \)) (Fig. 1).

Overall spasticity-related outpatient visits increased in the post-index period (mean (SD) 15.7 (23.8) and 18.9 (26.0) visits per patient in the pre- and post-index periods, respectively, \( p \leq 0.05 \), with significant increases observed for neurologist, physical medicine, and occupational therapy visits (Fig. 1).

### Table I. Patient demographics and baseline characteristics

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>OnabotulinumtoxinA (( N = 735 ))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male, ( n ) (%)</td>
<td>394 (54)</td>
</tr>
<tr>
<td>Age at index date, mean (SD)</td>
<td>60.7 (13.9)</td>
</tr>
<tr>
<td>Insurance type, ( n ) (%)</td>
<td></td>
</tr>
<tr>
<td>Commercial</td>
<td>479 (65.2)</td>
</tr>
<tr>
<td>Medicare</td>
<td>256 (34.8)</td>
</tr>
<tr>
<td>Patients with stroke diagnosis prior to first onabotulinumtoxinA claim( a ) (index date), ( n ) (%)</td>
<td></td>
</tr>
<tr>
<td>≤ 180 days</td>
<td>181 (33.4)</td>
</tr>
<tr>
<td>&gt; 180 days</td>
<td>361 (66.6)</td>
</tr>
<tr>
<td>≤ 365 days</td>
<td>420 (77.5)</td>
</tr>
<tr>
<td>&gt; 365 days</td>
<td>122 (22.5)</td>
</tr>
<tr>
<td>Charlson comorbidities within 12 months of index date, ( n ) (%)</td>
<td></td>
</tr>
<tr>
<td>Cerebrovascular disease( b )</td>
<td>735 (100)</td>
</tr>
<tr>
<td>Hemiplegia( b )</td>
<td>694 (94.4)</td>
</tr>
<tr>
<td>Diabetes without chronic complication</td>
<td>214 (29.1)</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>176 (23.9)</td>
</tr>
<tr>
<td>Chronic pulmonary disease</td>
<td>139 (18.9)</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>128 (17.4)</td>
</tr>
<tr>
<td>Diabetes with chronic complication</td>
<td>65 (8.8)</td>
</tr>
<tr>
<td>Any malignancy</td>
<td>65 (8.8)</td>
</tr>
<tr>
<td>Renal disease</td>
<td>61 (8.3)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>60 (8.2)</td>
</tr>
<tr>
<td>Mild liver disease</td>
<td>32 (4.4)</td>
</tr>
<tr>
<td>Dementia</td>
<td>31 (4.2)</td>
</tr>
<tr>
<td>Peptic ulcer disease</td>
<td>16 (2.2)</td>
</tr>
<tr>
<td>Rheumatic disease</td>
<td>11 (1.5)</td>
</tr>
<tr>
<td>Metastatic solid tumour</td>
<td>9 (1.2)</td>
</tr>
<tr>
<td>Moderate or severe liver disease</td>
<td>3 (0.4)</td>
</tr>
<tr>
<td>AIDS/HIV</td>
<td>1 (0.1)</td>
</tr>
</tbody>
</table>

\( a \) For the remainder of patients (26%), it was not possible to confirm stroke diagnosis based on medical history despite diagnosis of post-stroke spasticity and, therefore, they were omitted from sensitivity analysis. \( b \) These components of the Charlson Comorbidity Index were also represented among the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes for inclusion in this study. SD: standard deviation.
Impact on resource utilization of onabotulinumtoxinA for post-stroke spasticity

ED visits and hospital admissions 12 months before and after the first onabotulinumtoxinA treatment claim are shown in Fig. 2. Mean (SD) frequency of all-cause visits to the ED (1.1 (1.6) vs 0.8 (1.4); \( p \leq 0.0001 \)) and hospital admissions (1.5 (1.5) vs 0.4 (0.8); \( p \leq 0.0001 \)) per patient decreased significantly in the post-index vs the pre-index period. Significantly fewer patients had spasticity-related hospitalizations in the post-index period than in the pre-index period (Fig. 2).

Mean (SD) frequency of all-cause pharmacy fills was 43.0 (30.0) pre-index and 53.7 (39.7) post-index. There was a mean (SD) of 7.1 (8.2) spasticity-related pharmacy fills in the pre-index period and 10.1 (11.2) in the post-index period (\( p \leq 0.05 \)).

Cost outcomes

Compared with the 12 months before index onabotulinumtoxinA treatment, there was a 66% decrease in total all-cause costs (pre-index: United States dollars ($140,947; post-index: $48,553; \( p < 0.001 \)) and a 51% decrease in total spasticity-related costs (pre-index: $33,387; post-index: $16,198; \( p < 0.001 \)) observed in the post-index period, driven largely by a reduction in inpatient costs (Fig. 3). Increases in outpatient physician costs and pharmacy costs in the post-index period were offset by the decrease in inpatient costs (Fig. 3).

In the sensitivity analysis that evaluated change in 12-month costs before and after onabotulinumtoxinA treatment based on length of time from stroke diagnosis, there was a reduction in all-cause and spasticity-related costs in the post-index period for nearly all time-from-stroke-to-treatment subgroups (\( p < 0.0001 \)) (Fig. 4). These cost savings were maintained even in the subgroup of patients whose index date was most distant from the stroke event (>365 days; \( p < 0.0001 \)), although the magnitude of the reduction in costs was lessened further away from the stroke diagnosis (Fig. 4).

DISCUSSION

There is a high economic burden associated with stroke care (10–12), and healthcare costs are increased substantially for PSS (13, 14). BoNT/A (including onabotulinumtoxinA) is an effective treatment for PSS (19, 22, 23), and prior studies have assessed its cost-effectiveness for treating this condition (24, 25). However, there is currently little information about...
the impact of onabotulinumtoxinA treatment for PSS on overall HRU and costs for patients with stroke in real-world settings. In this analysis of data from a US claims database, we assessed HRU and costs before and after initiation of comprehensive spasticity management including onabotulinumtoxinA in patients with PSS. A strength of this analysis is the use of an administrative claims database allowing access to HRU and cost data from a large number of patients in a real-world setting across the USA.

There were significant reductions in all-cause ED visits and hospitalizations in the 12 months following treatment with onabotulinumtoxinA for PSS vs the 12-month pre-index period, as well as significant reductions in PSS-related hospital admissions. Overall, utilization of all-cause outpatient services was similar in the pre- and post-index periods, but there was variability by type. Significant increases in visits to neurologists, physical medicine specialists, and occupational therapists were observed, but significant reductions in primary care and other specialist visits were also observed. Total all-cause and spasticity-related costs decreased in the post-index period, driven largely by reductions in costs for inpatient care. Costs were reduced in the post-index period irrespective of length of time from stroke diagnosis (onabotulinumtoxinA treatment initiation within or after 180 days following stroke and within or after 365 days following stroke).

The increases in certain types of outpatient visits (i.e. neurologist, physical medicine specialist, occupational therapist) and pharmacy costs are consistent with patients initiating BoNT/A treatment for PSS and indicate that patients are receiving increased care
related to this medical issue. In patients who received onabotulinumtoxinA treatment, these increases were more than offset by the observed decreases in other categories of HRU and costs, as indicated by the overall decreases in total all-cause and spasticity-related costs.

These findings are consistent with prior resource use and cost-effectiveness modelling studies of BoNT/A treatment vs usual care (routine physical/occupational therapy) or oral therapy (24, 25). In 2005, Ward et al. (25) developed a decision-tree model to analyse data from a Delphi panel survey involving 15 UK clinicians and patients with flexed-wrist/clenched-fist spasticity. Notwithstanding the bias inherent in relying on expert opinion for outcome assessment, treatment with BoNT/A as first- or second-line therapy was 1.8–1.2 times more cost-effective than oral therapy in terms of number of successfully treated months per year (i.e. months in which benefit was sufficient to continue treatment) (25). Fewer nurse hours, but more physiotherapist hours, were required for patients receiving BoNT/A than for those receiving oral therapy (25).

In 2013, Doan et al. (24) developed a simulation model based on clinical trial data to compare the cost of usual care plus onabotulinumtoxinA with usual care alone for the treatment of upper-limb PSS. Although usual care plus onabotulinumtoxinA treatment increased direct medical costs compared with usual care alone, the combination therapy was associated with reduced patient disability, increased quality-adjusted life-years, and reduced caregiver burden, and was considered cost-effective in this patient population (24).

Claims database analyses ensure the benefit of large, diverse sample sizes with longitudinal follow-up and lack of selection bias; however, certain limitations should be considered when interpreting the results of this study, owing to the type of data available. One limitation of the current analysis is the potential bias associated with the small cohort of 735 patients who received onabotulinumtoxinA for PSS and met all inclusion criteria. There are healthcare access issues at play in this regard, as there is a variable level of comfort with using toxins as a treatment for PSS across patients and healthcare providers. We chose to limit the attrition to patients with 12 months of continuous enrolment before and after initial spasticity diagnosis to check for use of onabotulinumtoxinA in the 12 months before spasticity diagnosis. This was to identify true new starts to onabotulinumtoxinA. A significant number of patients received onabotulinumtoxinA within 12 months of stroke diagnosis, and this contributed to the high pre-period costs. Spasticity-related costs would not be impacted by HRU and cost of the stroke event itself. Nevertheless, the lack of a random study sample and requirement for included patients to have continuous plan enrolment may limit the generalizability of the study findings. Furthermore, because claims data do not include key confounding information about stroke and spasticity severity, we were unable to develop and compare outcomes to an appropriately matched cohort of patients not receiving onabotulinumtoxinA treatment, given that patients not receiving onabotulinumtoxinA treatment are likely to have less severe spasticity. Consequently, it is difficult to isolate the contribution of onabotulinumtoxinA treatment to the overall cost of care for these patients. In addition, the current cost analysis does not take into account the potential for other benefits of effective treatment for PSS, including gains in patient quality of life and functioning and decreases in caregiver burden, which also can have important indirect economic consequences (16).

In conclusion, all-cause and spasticity-related HRU and costs decreased significantly in the 12 months following initiation of spasticity management including onabotulinumtoxinA treatment, suggesting that onabotulinumtoxinA may help to alleviate the economic burden associated with PSS, although this study did not demonstrate causality between onabotulinumtoxinA treatment and HRU and cost reductions. In the sensitivity analysis, cost savings in the post-index period relative to the pre-index period were largely maintained irrespective of time between stroke and initiation of onabotulinumtoxinA. The data presented reflect HRU in the USA, and similar data have been used in other countries to support the value of onabotulinumtoxinA treatment in the management of spasticity (24, 25). Further long-term controlled studies would be needed to establish a causative role for onabotulinumtoxinA treatment in the declining HRU and costs associated with PSS observed in this retrospective claims database analysis.

ACKNOWLEDGEMENTS

AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and was funded by AbbVie.

Conflicts of interest and funding disclosure. AE has served as scientific advisor to and has received research support from Allergan (now AbbVie) and Ipsen. MV-G has been a paid consultant or on an advisory board for AbbVie, Ipsen, Medtronic, and Merz. She has a re-
Impact on resource utilization of onabotulinumtoxinA for post-stroke spasticity

This study was sponsored by AbbVie.

REFERENCES


